Subcutaneous ivermectin for the treatment of the hyperinfection syndrome by Strongyloides stercoralis

Diana Carolina Hennessey, Óscar Andrés Ballesteros, Diego Javier Merchán, Freddy Orlando Guevara, Diego Fernando Severiche, .

Keywords: Strongyloidiasis/drug therapy, ivermectin, subcutaneous injection, intestinal obstruction, immunosuppression

Abstract

Strongyloidiasis is a disease caused by the nematode Strongyloides stercoralis that is endemic in rural regions in tropical and subtropical countries. Immunosuppressed patients have an increased risk of infection by this parasite and are at risk of developing a hyperinfection syndrome which involves a higher risk of death. The syndrome is treated with ivermectin, however, there is no parenteral presentation of this medication for human use in Colombia or the world, which is an important problem in patients who have compromised enteral absorption, for instance, those with intestinal obstructions.
We present a case of hyperinfection syndrome by Strongyloides stercoralis in Colombia, which was treated with subcutaneous ivermectin. Our purpose is to encourage pharmacokinetic and pharmacodynamic studies to establish this route of administration in the future as an alternative for those patients who have a high risk of therapeutic failure with the oral route.

Downloads

Download data is not yet available.
  • Diana Carolina Hennessey Departamento de Medicina Interna, Universidad El Bosque, Bogotá, D.C., Colombia
  • Óscar Andrés Ballesteros Departamento de Medicina Crítica y Cuidado Intensivo, Universidad del Rosario, Bogotá, D.C., Colombia
  • Diego Javier Merchán Departamento de Medicina Crítica y Cuidado Intensivo, Universidad del Rosario, Bogotá, D.C., Colombia
  • Freddy Orlando Guevara Servicio de Infectología, Fundación Santafé de Bogotá, Bogotá, D.C., Colombia
  • Diego Fernando Severiche Departamento de Medicina Interna, Universidad de La Sabana, Chía, Colombia https://orcid.org/0000-0002-0976-3093

References

Kassalik M, Mönkemüller K. Strongyloides stercoralis hyperinfection syndrome and disseminated disease. Gastroenterol Hepatol. 2011;7:766-8.

Greaves D, Coggle S, Pollard C, Aliyu SH, Moore EM. Strongyloides stercoralis infection. BMJ. 2013;347:f4610. https://doi.org/10.1136/bmj.f4610

Roxby AC, Gottlieb GS, Limaye AP. Strongyloidiasis in transplant patients. Clin Infect Dis. 2009;49:1411-23. https://doi.org/10.1086/630201

Marcos LA, Terashima A, Dupont HL, Gotuzzo E. Strongyloides hyperinfection syndrome: An emerging global infectious disease. Trans R Soc Trop Med Hyg. 2008;102:314-8. https://doi.org/10.1016/j.trstmh.2008.01.020

Hernández-Chavarría F. Strongyloides stercoralis: un parásito subestimado. Parasitol Día. 2001;25:40-9. https://doi.org/10.4067/S0716-07202001000100008

Schär F, Trostdorf U, Giardina F, Khieu V, Muth S, Marti H, et al. Strongyloides stercoralis: Global distribution and risk factors. PLoS Negl Trop Dis. 2013;7:e2288. https://doi.org/10.1371/journal.pntd.0002288

Puthiyakunnon S, Boddu S, Li Y, Zhou X, Wang C, Li J, et al. Strongyloidiasis—an insight into its global prevalence and management. PLoS Negl Trop Dis. 2014;8:e3018. https://doi.org/10.1371/journal.pntd.0003018

Buonfrate D, Mena MA, Angheben A, Requena-Méndez A, Muñoz J, Gobbi F, et al. Prevalence of strongyloidiasis in Latin America: A systematic review of the literature. Epidemiol Infect. 2015;143:452-60. https://doi.org/10.1017/S0950268814001563

Center for Disease Control and Prevention. Strongyloidiasis. Fecha de consulta: 20 de febrero de 2019. Disponible en: https://www.cdc.gov/parasites/strongyloides/index.html

Llagunes J, Mateo E, Peña JJ, Carmona P, Andrés J. Hiperinfección por Strongyloides stercoralis. Med Intensiva. 2010;34:353-6. https://doi.org/10.1016/j.medin.2009.06.006

Lim S, Katz K, Krajden S, Fuksa M, Keystone JS, Kain KC. Complicated and fatal Strongyloides infection in Canadians: Risk factors, diagnosis and management. CMAJ. 2004;171:479-84. https://doi.org/10.1503/cmaj.1031698

Segarra-Newnham M. Manifestations, diagnosis, and treatment of Strongyloides stercoralis infection. Ann Pharmacother. 2007;41:1992-2001. https://doi.org/10.1345/aph.1K302

Barrett J, Broderick C, Soulsby H, Wade P, Newsholme W. Subcutaneous ivermectin use in the treatment of severe Strongyloides stercoralis infection: Two case reports and a discussion of the literature. J Antimicrob Chemother. 2016;71:220-5. https://doi.org/10.1093/jac/dkv315

Chiodini PL, Reid AJ, Wiselka MJ, Firmin R, Foweraker J. Parenteral ivermectin in Strongyloides hyperinfection. Lancet. 2000;355:43-4 https://doi.org/10.1016/s0140-6736(99)02744-0

Zeitler K, Jariwala R, Restrepo-Jaramillo R, Kapadia S, Casanas B, Sriaroon C, et al. Successful use of subcutaneous ivermectin for the treatment of Strongyloides stercoralis hyperinfection in the setting of small bowel obstruction and paralytic ileus in the immunocompromised population. BMJ Case Rep. 2018;2018:bcr-2017-223138. https://doi.org/10.1136/bcr-2017-223138

How to Cite
1.
Hennessey DC, Ballesteros Óscar A, Merchán DJ, Guevara FO, Severiche DF. Subcutaneous ivermectin for the treatment of the hyperinfection syndrome by Strongyloides stercoralis. biomedica [Internet]. 2020 Jun. 15 [cited 2024 May 19];40(2):228-32. Available from: https://revistabiomedica.org/index.php/biomedica/article/view/5140

Some similar items:

Published
2020-06-15
Section
Case presentation

Altmetric

Article metrics
Abstract views
Galley vies
PDF Views
HTML views
Other views
QR Code